Figure 3.
Kaplan‐Meier survival curves for progression‐free survival are plotted for (a) overall population with at least 6 months of follow‐up, (b) those receiving clinical trial therapy and routine clinical practice therapy, (c) those receiving biomarker‐directed therapy and non‐biomarker‐directed therapy. CI, confidence interval; CNS, central nervous system; CUP, carcinoma of unknown primary; FDA, US Food and Drug Administration; M. MENINGIOMA, malignant meningioma; PFS, progression‐free survival; PNS, peripheral nervous system.